Ultragenyx Pharmaceutical

Healthcare biotech drug development genetics pharma

Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. It is creating an improved model for successful rare disease drug development that increases efficiency and effectiveness by changing the way the process is organized and conducted. The Company believes that it can deliver significant value to its patients by building a diverse and high quality pipeline of rare disease therapeutics and efficiently transforming good science into great medicine.

Revenue(FY, 2016)

$133 K

Market capitalization(2018-09-14)

$4.4 B

Type	Public
HQ	Novato, US
Founded	2010
Size (employees)	376 (est)
Website	ultragenyx.com

Ultragenyx Pharmaceutical was founded in 2010 and is headquartered in Novato, US

Report incorrect company information

Viewing summary data as a guest

Key People/Management at Ultragenyx Pharmaceutical

Emil D. Kakkis

Chief Executive Officer and President

Camille Bedrosian

Chief Medical Officer and Executive Vice President

Wladimir Hogenhuis

COO

Dennis Huang

Chief Technical Operations Officer and Executive Vice President

Thomas Kassberg

Chief Business Officer and Executive Vice President

Karah Parschauer

General Counsel and Executive Vice President

Report incorrect company information

Ultragenyx Pharmaceutical Office Locations

Open Map View

Ultragenyx Pharmaceutical has an office in Novato

Novato, US (HQ)

60 Leveroni Ct

Show all (1)

Report incorrect company information

Ultragenyx Pharmaceutical Financials and Metrics

Ultragenyx Pharmaceutical Revenue

Ultragenyx Pharmaceutical's revenue was reported to be $133 k in FY, 2016

Summary

USD
Revenue (Q2, 2018)	23.5 m
Gross profit (Q2, 2018)	23.1 m
Gross profit margin (Q2, 2018), %	98.4%
Net income (Q2, 2018)	(22.5 m)
EBIT (Q2, 2018)	(191.4 m)
Market capitalization (14-Sep-2018)	4.4 b
Closing stock price (14-Sep-2018)	86.8
Cash (30-Jun-2018)	110.9 m

Ultragenyx Pharmaceutical's current market capitalization is $4.4 b.

Income Statement

Annual

USD	FY, 2014	FY, 2015	FY, 2016
Revenue			133 k
General and administrative expense	10.8 m	33 m	64.9 m
R&D expense	46 m	114.7 m	183.2 m
Operating expense total	56.8 m	147.7 m	248.1 m

Quarterly

show all

Balance Sheet

Annual

USD	FY, 2014	FY, 2015	FY, 2016
Cash	24.3 m	93.6 m	161.1 m
Inventories	5.9 m	13.1 m	20.1 m
Current Assets	193.4 m	450.2 m	401.7 m
PP&E	3 m	7.4 m	17.1 m

Quarterly

USD	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q1, 2018	Q2, 2018
Cash	178 m	52.4 m	166.7 m	70.8 m	55.1 m	142.3 m	159.5 m	90.8 m	226.7 m	110.9 m
Accounts Receivable									3.7 m	17.4 m
Inventories									2.1 m	3.3 m
Current Assets	350.5 m	336.5 m	460.7 m	430.2 m	411.1 m	416.8 m	444.7 m	419.8 m	581.6 m	604.7 m

show all

Cash Flow

Annual

USD	FY, 2014	FY, 2015	FY, 2016
Net Income	(59.8 m)	(145.6 m)	(245.9 m)
Depreciation and Amortization	684 k	1.4 m	3.4 m
Inventories	(4.1 m)	(7.1 m)	(7.1 m)
Accounts Payable	3.2 m	(2 m)	2.5 m

Quarterly

USD	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q1, 2018	Q2, 2018
Net Income				(21.4 m)	(29.8 m)	(39.2 m)	(52.8 m)	(56.9 m)	(64.9 m)	(68.3 m)	30.3 m	(22.5 m)
Depreciation and Amortization											6.2 m	12.2 m
Accounts Payable	3.5 m	3.6 m	4.2 m	5.8 m	10.2 m	4.4 m	6 m	7 m	6.6 m	8.3 m	(1.3 m)	1.4 m
Cash From Operating Activities											(89.5 m)	(165.6 m)